Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Etcembly
Etcembly is an AI-driven drug discovery company focused on pioneering novel immunotherapies, particularly TCR and antibody design. Their core technology, EMLy™, is a repertoire decoding platform…
Etcembly
Etcembly is an AI-driven drug discovery company focused on pioneering novel immunotherapies, particularly TCR and antibody design. Their core technology, EMLy™, is a repertoire decoding platform…
TL;DR
Founded: 2020
Headquarters: Harwell Campus, Oxfordshire, United Kingdom
Core tech: EMLy™ — protein-specific LLMs & generative AI for TCR/antibody design
Industry: Biotechnology (AI-driven biologics discovery)
Reported funding: Seed round closed (oversubscribed, private syndicate); ~ $20M reported in summaries
Company Overview
Problem Domain
Biologics discovery and optimisation for immunotherapies (TCRs, antibodies and related modalities).
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
Closed oversubscribed private seed round (syndicate incl. private & institutional investors)
Company describes the round as oversubscribed and backed by a mix of private and institutional investors; summaries reference ~ $20M raised but specific rounds/dates not provided in evidence
Investor Signal
“Backed by a mix of private and institutional investors (seed syndicate, includes Singapore VC participation in summaries)”
Founders
What we do
Join the Team
Startup jobs. A lot of them.
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
66,000+
Open Roles
1,300+
New This Week